Vincristine
- Generic Name
- Vincristine
- Brand Names
- Marqibo, Vincasar
- Drug Type
- Small Molecule
- Chemical Formula
- C46H56N4O10
- CAS Number
- 57-22-7
- Unique Ingredient Identifier
- 5J49Q6B70F
- Background
Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy).
- Indication
Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
- Associated Therapies
- -
MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma
- First Posted Date
- 2011-08-12
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT01415765
A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)
- Conditions
- Interventions
- First Posted Date
- 2011-08-11
- Last Posted Date
- 2018-04-25
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT01414855
- Locations
- 🇺🇸
Norwalk Hospital, Norwalk, Connecticut, United States
🇺🇸Onc Hem Assoc of Central IL, Peoria, Illinois, United States
🇺🇸Florida Cancer Specialists; Saint Petersburg, Saint Petersburg, Florida, United States
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
- First Posted Date
- 2011-07-21
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 91
- Registration Number
- NCT01399372
- Locations
- 🇺🇸
Fresno Cancer Center, Fresno, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine
- Conditions
- Interventions
- First Posted Date
- 2011-07-20
- Last Posted Date
- 2018-03-27
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT01397825
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
- First Posted Date
- 2011-07-11
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 6
- Registration Number
- NCT01390584
- Locations
- 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center, Reading, Pennsylvania, United States
Treatment of Acute Lymphoblastic Leukemia Ph '(BCR / ABL) Positive Patients Aged > 55 Years
- Conditions
- First Posted Date
- 2011-06-20
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 100
- Registration Number
- NCT01376427
- Locations
- 🇪🇸
Hospital Germans Trias i Pujol and all Hospital Pethema, Badalona, Barcelona, Spain
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
- Conditions
- High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsRecurrent Burkitt LymphomaB Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeBurkitt-Like Lymphoma With 11q AberrationRecurrent B Acute Lymphoblastic LeukemiaHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedRefractory B Acute Lymphoblastic LeukemiaRefractory Burkitt LymphomaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Interventions
- First Posted Date
- 2011-06-13
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 276
- Registration Number
- NCT01371630
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001)
- Conditions
- Interventions
- First Posted Date
- 2011-06-10
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 7
- Registration Number
- NCT01370694
Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia
- First Posted Date
- 2011-05-23
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT01358253
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years
- Conditions
- First Posted Date
- 2011-05-23
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 100
- Registration Number
- NCT01358201
- Locations
- 🇪🇸
Hospital de Alcorcón, Alcorcón, Spain
🇪🇸Hospital Germans Trias i Pujol, Badalona, Spain
🇪🇸Fundación Hospital Alcorcón, Alcorcón, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.